HFE C282Y

HFE C282Y — The Iron Overload Variant

The HFE gene encodes the hereditary hemochromatosis protein | A membrane protein structurally similar to MHC class I molecules that regulates iron absorption by sensing blood iron levels and modulating hepcidin expression,
a key regulator of iron homeostasis. A single G-to-A change at nucleotide 845
replaces cysteine with tyrosine at position 282 of the protein, destroying a
critical disulfide bond in the alpha-3 domain | The immunoglobulin-like C1-set domain that mediates binding to beta-2 microglobulin, essential for proper protein folding and cell surface expression.
This variant — universally known as C282Y — is the primary cause of hereditary
hemochromatosis type 1, the most common autosomal recessive condition in people
of European descent.

The Mechanism

HFE normally forms a complex with beta-2 microglobulin | A small protein that stabilizes MHC class I and class I-like molecules, enabling their transport to the cell surface
and travels to the cell surface, where it interacts with transferrin receptors
(TfR1 and TfR2) to sense circulating iron levels. When iron is sufficient, this
signaling cascade stimulates the liver to produce hepcidin | The master iron-regulatory hormone; it blocks ferroportin, the only known cellular iron exporter, thereby reducing iron absorption from the gut and iron release from macrophages,
which in turn blocks iron absorption from the intestine by degrading
ferroportin | The sole known iron export channel on intestinal epithelial cells and macrophages
on gut cells.

The C282Y mutation prevents HFE from binding beta-2 microglobulin. Without this
partner, the protein cannot fold correctly, never reaches the cell surface, and
accumulates uselessly inside the cell. The result is a broken iron sensor:
the liver produces inappropriately low hepcidin regardless of how much iron is
already in the body. With the brake removed, the gut absorbs 2-3 times more
dietary iron than normal, and macrophages release stored iron unchecked. Over
decades, this excess iron deposits in the liver, heart, pancreas, and joints.

The Evidence

The landmark 1996 discovery | Feder JN et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996
by Feder and colleagues identified the HFE gene and found C282Y homozygosity in
83% of hereditary hemochromatosis patients. This remains the most common genetic
cause of iron overload worldwide.

The Melbourne Collaborative Cohort Study | Allen KJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med, 2008
followed 31,192 persons of European descent for 12 years. Among 203 C282Y
homozygotes, iron-overload-related disease developed in 28.4% of men but only
1.2% of women — highlighting the dramatic sex difference in clinical penetrance.
Men are far more vulnerable because they lack the protective iron losses from
menstruation.

A UK Biobank analysis | Pilling LC et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ, 2019
of 451,243 participants confirmed that C282Y homozygous men have significantly
higher rates of liver disease (HR 2.22), diabetes (HR 1.72), and arthritis
compared with non-carriers. Hemochromatosis was diagnosed in 21.7% of
homozygous men by end of follow-up.

A meta-analysis of 43 study populations | Bacon BR et al. Hemochromatosis genotypes and risk of iron overload — a meta-analysis. Genet Med, 2011
pooling 9,986 cases and 25,492 controls established C282Y homozygosity as the
overwhelmingly dominant genetic risk factor for both biochemical and clinical
iron overload.

Practical Implications

For AA (C282Y homozygous) individuals: you carry the highest-risk genotype for
hereditary hemochromatosis. Regular serum ferritin and transferrin saturation
monitoring is essential. If iron levels are elevated, therapeutic phlebotomy
(regular blood removal) is the standard treatment and is highly effective when
started before organ damage occurs. Limit iron-fortified foods and high-dose
vitamin C supplements, which enhance iron absorption. Avoid excess red meat
and iron-containing multivitamins.

For AG (heterozygous carrier) individuals: you carry one copy of C282Y. Your
iron levels may run slightly higher than average, which is generally benign and
may even protect against iron deficiency anemia. Routine ferritin screening
every few years is reasonable. Significant iron overload from heterozygosity
alone is rare.

For GG (wild-type) individuals: you have normal HFE function at this locus.
Standard dietary iron recommendations apply.

Interactions

The most clinically significant interaction is with
H63D (rs1799945) | HFE H63D is a milder variant in the same gene; compound heterozygosity (one C282Y + one H63D) confers a small risk of mild iron overload
in the same gene. Compound heterozygosity — carrying one C282Y allele and one
H63D allele — produces a mildly elevated risk of iron overload, though far less
than C282Y homozygosity. A study of compound heterozygotes | Walsh A et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology, 2009
found that documented iron-overload-related disease occurred in only about 1-2%
of C282Y/H63D compound heterozygotes, similar to wild-type rates. However, mean
serum ferritin and transferrin saturation were significantly elevated compared
with non-carriers, so monitoring remains reasonable.

If a user carries C282Y heterozygous (AG at rs1800562) plus H63D heterozygous
(CG at rs1799945), a compound implication should advise periodic ferritin
monitoring, as the combination slightly amplifies iron absorption beyond either
variant alone. This interaction is well-documented but low-penetrance.